Heart Failure

The International Diabetes Federation estimated that 10% of adults (20–79 years old) worldwide had diabetes in 2021 (i.e., 537 million people); this number is predicted to rise to 783 million by 2045 [ 1 ]. In the United States (US), an estimated …

68 Ga-labeled fibroblast activation protein (FAP) inhibitor (FAPi) is a positron emission tomography (PET) tracer, whose use has been consistently increasing in recent years, especially in the oncological field [ 1 ]. This tracer targets a …

Heart failure (HF) is a chronic and progressive condition affecting millions of people worldwide that poses substantial challenges to patients, caregivers, and healthcare systems. Despite significant advancements in medical treatments, HF remains …

Cardiology and sensor technology have significantly evolved over the last century and now their intersection has further expanded remote patient care. From Laennec’s stethoscope [ 1 , 2 ] to the newest ultrasound patch [ 1 , 2 ], cardiology has …

Impaired myocardial mechano-energetics efficiency (MEE) was shown to predict incident heart failure, but pathophysiological mechanisms linking impaired MEE with heart failure have not been elucidated. Endothelial dysfunction is a plausible …

The International Diabetes Federation estimated that 10% of adults (20–79 years old) worldwide had diabetes in 2021 (i.e., 537 million people); this number is predicted to rise to 783 million by 2045 [ 1 ]. In the United States (US), an estimated …

68 Ga-labeled fibroblast activation protein (FAP) inhibitor (FAPi) is a positron emission tomography (PET) tracer, whose use has been consistently increasing in recent years, especially in the oncological field [ 1 ]. This tracer targets a …

Heart failure (HF) and permanent atrial fibrillation (AF) interact mutually, exacerbating hemodynamic effects and causing adverse outcomes and increased healthcare costs. Monitoring hemodynamic indicators in patients with these comorbidities is …